Capmatinib (Incyte/Novartis) is an orally bioavailable inhibitor of the proto-oncogene c-MET, also called hepatocyte growth factor receptor (HGFR). C-MET is a receptor tyrosine kinase, and abnormal activation in cancer can trigger tumor growth, angiogenesis, and metastasis. As a result, patients with aberrant c-MET activity typically have poor prognosis, aggressive disease, and shortened survival. Capmatinib selectively binds to c-MET, thereby disrupting c-MET signaling pathways. This can induce cell death in tumor cells with high c-MET amplification.
4 Drug Overview
5 Product Profiles
5 capmatinib : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
9 Figure 29: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
10 Figure 31: Imfinzi for non-small cell lung cancer – SWOT analysis
11 Figure 52: Tagrisso sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
13 Figure 63: Datamonitor Healthcare’s drug assessment summary for Tecentriq in non-small cell lung cancer
LIST OF TABLES
6 Table 1: Capmatinib drug profile
7 Table 2: Capmatinib pivotal in non-small cell lung cancer
8 Table 3: Capmatinib early-phase data in non-small cell lung cancer
177 Table 44: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
16 Table 5: Capmatinib patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.